LBPH

Analyst Sentiment

Wall St. Consensus
Buy
9 analysts·Limited coverage
64
Score
5 Buy (56%)4 Hold (44%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
556%
Hold
444%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$16.00
-73.3%
Consensus
$60.00
+0.0%
Bull
$90.00
+50.1%
12-Month Target Range9 analysts
$16.00$60.00$90.00
Current $59.98Consensus
Current Price
$59.98
Upside to Consensus
$0.02

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+922.78%
EPS
FY2028
Rev+369.89%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028E
Revenue Avg$5M$51M$240M
Low$5M$51M$240M
High$5M$51M$240M
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-74M$-71M$-15M
Low$-80M$-71M$-15M
High$-67M$-71M$-15M
EPS Avg$-3.23$-3.12$-0.66
Low$-3.53$-3.12$-0.66
High$-2.94$-3.12$-0.66
Analysts (Rev / EPS)6 / 63 / 22 / 3

Earnings Surprises

Recent Analyst Actions

Oct 14, 2024B.Riley Financial
B.Riley Downgrades Longboard Pharmaceuticals Inc (LBPH) to Neutral
Target:$60.00
+2.0%from $58.83
Sep 18, 2024H.C. Wainwright
Longboard Pharmaceuticals Inc (LBPH) PT Raised to $80 at H.C. Wainwright
Target:$80.00
+190.1%from $27.58
Sep 10, 2024Truist Financial
Longboard Pharmaceuticals initiated with a Buy at Truist
Target:$60.00
+73.9%from $34.51
Sep 6, 2024Robert W. Baird
Baird Reiterates Outperform Rating on Longboard Pharmaceuticals Inc (LBPH)
Target:$60.00
+77.0%from $33.89
Jul 1, 2024Cantor Fitzgerald
Longboard price target raised to $90 from $60 at Cantor Fitzgerald
Target:$90.00
+212.9%from $28.76
Jun 10, 2024B.Riley Financial
Longboard Pharmaceuticals Inc (LBPH) PT Raised to $36 at B.Riley
Target:$36.00
+98.8%from $18.11
Apr 30, 2024Robert W. Baird
Longboard initiated with an Outperform at Baird on 'best-in-class potential
Target:$36.00
+69.0%from $21.30
Nov 11, 2022Guggenheim
Guggenheim Maintains Buy on Longboard Pharmaceuticals, Lowers Price Target to $16
Target:$16.00
+247.8%from $4.60
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.